Abstract: The present disclosure is based, at least in part, on providing a set of markers, also referred to herein as FXN-sensitive lipid markers (or FSLMs), the respective levels of which are positively or negatively correlated to frataxin (FXN) levels in a cell. Therefore, these FSLMs can be used to determine, evaluate, and/or monitor the effectiveness of FXN replacement therapy in a subject.

Abstract: Disclosed are various lipid biomarkers of inflammatory bowel disease, including biomarkers for inflammatory bowel diseases including Crohn’s disease and Ulcerative colitis. Also disclosed are various biomarkers of disease location and/or disease behavior in inflammatory bowel disease. The present disclosure also provides methods of using the biomarkers, including methods for diagnosis of inflammatory bowel disease, methods of determining predisposition to inflammatory bowel disease, methods of monitoring progression/regression of inflammatory bowel disease, and methods of assessing efficacy of compositions for treating inflammatory bowel disease.